From: Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia
TDT (n = 54) | NTDT (n = 23) | All Patients (n = 77) | Controls (n = 56) | |
---|---|---|---|---|
mean age, years | 36.4 ± 9.2 | 30.3 ± 11.5 | 34.6 ± 10.5 | 33.9 ± 10.8 |
Females, n(%) | 34 (62.9) | 13 (56%) | 47 (61.0) | 36 (64.3) |
Splenectomized, n (%) | 35 (64.8) | 9 (39%) | 44 (57.1) | 0 |
Hb*(g/dl), mean ± SD | 9.2 ± 0.5 | 9.3 ± 0.9 | 9.3 ± 0.8 | NA |
Hb at MRI (g/dl), mean ± SD | 9.6 ± 1.1 | 9.3 ± 0.9 | 9.5 ± 1 | NA |
Ferritin (ng/ml), mean ± SD | 877.0 ± 684.4 | 364.1 ± 290.8 | 736.2 ± 641.7 | NA |
LIC (mg/gdw), mean ± SD | 4.3 ± 3.0 | 6.7 ± 5.4 | 4.9 ± 3.7 | NA |
Iron Chelation Therapy | ||||
DFO ever, n (%) | 50 (92.6) | 6 (26.1) | 56 (72.7) | 0 |
ongoing, n (%) | 14 (25.9) | 2 (8.7) | 16 (20.8) | 0 |
current dose, mg/kg | 35.8 ± 3.0 | 20.0 ± 1.6 | 33.5 ± 6.4 | 0 |
DFP ever, n (%) | 21 (38.9) | 0 | 21 (27.3) | 0 |
ongoing, n (%) | 4 (7.4) | 0 | 5 (6.5) | 0 |
current dose, mg/kg | 73.6 ± 2.4 | 0 | 73.6 ± 2.4 | 0 |
DFX ever, n (%) | 50 (92.6) | 8 (34.8) | 58 (75.3) | 0 |
ongoing, n (%) | 35(64.8) | 4 (17.4) | 38 (49.3) | 0 |
current dose, mg/kg | 27.8 ± 8.1 | 10.1 ± 0.6 | 21.5 ± 10.4 | 0 |